After serving two years as CEO of Novo A/S, a subsidiary of the Novo Nordisk Foundation, Eivind Kolding is resigning as of 29 February 2016.

Before a new CEO is appointed, Sten Scheibye, Chairman of Novo A/S, will assume the role of CEO on an interim basis.